N.Y. Federal Judge Allows Farxiga Off-Label Promotion Actions to Proceed

NEW YORK - The judge overseeing the national coordinated docket for Farxiga lawsuits has refused to dismiss three actions accusing the manufacturer defendants of promoting the type 2 diabetes drug for off-label purposes and failing to adequately warn of the risk of diabetic ketoacidosis.

On March 9, Judge Lorna G. Schofield of the U.S. District Court for the Southern District of New York denied defendants' consolidated motion to dismiss, thereby allowing claims of off-label marketing, negligent testing, and gross negligence to proceed against Bristol-Myers Squibb Co., AstraZeneca LP, and AstraZeneca Pharmaceuticals LP.

Texas residents Chaim Aron, Cherie Perez and Arquimedes …